Accelerated Approval for IgA Nephropathy Treatment

Dana Rizk, MD, Professor of Medicine at the University of Alabama at Birmingham, discusses the U.S. Food and Drug Administration (FDA) accelerated approval of Fabhalta (iptacopan) for the reduction of proteinuria in adults with IgA nephropathy (IgAN).    ...